IVX Stock Overview
A clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia.
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Invion Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | AU$0.002 |
| 52 Week High | AU$0.008 |
| 52 Week Low | AU$0.002 |
| Beta | 1.13 |
| 11 Month Change | -42.86% |
| 3 Month Change | -33.33% |
| 1 Year Change | -66.67% |
| 33 Year Change | -91.30% |
| 5 Year Change | -81.82% |
| Change since IPO | -96.92% |
Recent News & Updates
Recent updates
Shareholder Returns
| IVX | AU Pharmaceuticals | AU Market | |
|---|---|---|---|
| 7D | -20.0% | -2.3% | -1.1% |
| 1Y | -66.7% | 61.9% | 16.1% |
Return vs Industry: IVX underperformed the Australian Pharmaceuticals industry which returned 69.7% over the past year.
Return vs Market: IVX underperformed the Australian Market which returned 17.9% over the past year.
Price Volatility
| IVX volatility | |
|---|---|
| IVX Average Weekly Movement | 30.6% |
| Pharmaceuticals Industry Average Movement | 11.9% |
| Market Average Movement | 8.7% |
| 10% most volatile stocks in AU Market | 17.7% |
| 10% least volatile stocks in AU Market | 3.6% |
Stable Share Price: IVX's share price has been volatile over the past 3 months compared to the Australian market.
Volatility Over Time: IVX's weekly volatility (31%) has been stable over the past year, but is still higher than 75% of Australian stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | n/a | Thian Chew | www.inviongroup.com |
Invion Limited, a clinical-stage life-sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company is developing IVX-PDT, a photosensitizer agent to treat skin cancers, and solid cancers, such as lung, ovarian, anogenital, and glioblastoma multiforme cancers. It has a research and development agreement with Hudson Institute of Medical Research to develop a novel photosensitiser for the treatment of a range of cancers; and research agreement with Peter MacCallum Cancer Centre to undertake pre-clinical and in-vitro studies on Invion’s IVX-PDT Photodynamic therapy for ano-genital cancers, including penile and anal cancer.
Invion Limited Fundamentals Summary
| IVX fundamental statistics | |
|---|---|
| Market cap | AU$13.53m |
| Earnings (TTM) | -AU$5.63m |
| Revenue (TTM) | AU$3.69m |
3.7x
P/S Ratio-2.4x
P/E RatioIs IVX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| IVX income statement (TTM) | |
|---|---|
| Revenue | AU$3.69m |
| Cost of Revenue | AU$2.69m |
| Gross Profit | AU$1.00m |
| Other Expenses | AU$6.63m |
| Earnings | -AU$5.63m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00083 |
| Gross Margin | 27.16% |
| Net Profit Margin | -152.34% |
| Debt/Equity Ratio | 0% |
How did IVX perform over the long term?
See historical performance and comparison